SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: Tunica Albuginea who wrote (4418)1/8/1998 11:18:00 AM
From: Gene Voss  Read Replies (1) | Respond to of 23519
 
TA: I refered to this very concern in a recent post.Bias is very easily introduced in a study even when obectivity is a priority.I agree with the contention that company funded research should continue. Financial disclosure would help prevent obvious bias since the investigator would know a conflict of interest is suspected if he has a strong financial tie to the product he is evaluating.It would also encourage him to design a study as devoid of bias as possible since his financial ties are known,he would know his study will be viewed with intense scrutiny.
Human evaluation error is always something to be aware of and an honest evaluation the goal.Unfortunately these are difficult times financially in medicine so investigators are under intense pressure to please their benefactors.

GV



To: Tunica Albuginea who wrote (4418)1/8/1998 7:29:00 PM
From: BigKNY3  Read Replies (1) | Respond to of 23519
 
TA: Gee, here you had me all convinced that physicians are only concerned about "patient concerns" and remain unbiased due to financial considerations.....Does this now apply to physicians who own stock in pharmaceutical companies? Should we demand full disclosure on our posts?

What was missing from the Toronto study was an analysis of the payments made to the calcium channel blocker critics by competitive antihypertensive companies. I bet it would have been very revealing.

Basically, the study revealed nothing new. The pharmaceutical industry supports the leaders in the field and investigators who agree with their point of view. Hard to debate this logic.

BigKNY3

Full Disclosure: Own stock in VVUS, PFE, WLA, MRK, LLY, & AMGN